![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
|Articles|September 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 9
- Volume 4
- Issue 9
Michigan Cancer System Named for Woman
DETROIT--The Michigan Cancer Foundation has received a $15 million gift from Peter Karmanos, Jr., chairman and CEO of Compuware Corporation, Farmington Hills, Michigan.
Advertisement
DETROIT--The Michigan Cancer Foundation has received a $15 milliongift from Peter Karmanos, Jr., chairman and CEO of Compuware Corporation,Farmington Hills, Michigan.
The gift, the largest ever to fight cancer in Michigan, will benefitthe integrated cancer system formed by the Michigan Cancer Foundation,the Meyer L. Prentis Comprehensive Cancer Center of MetropolitanDetroit, and the cancer programs of the Detroit Medical Centerand Wayne State University.
The system is now called the Barbara Ann Karmanos Cancer Institute,in memory of Mr. Karmanos' first wife who died of breast cancerin 1989 at the age of 46. It is the only nationally recognizedcenter to be named for a woman.
The Institute, headed by William P. Peters, MD, PhD, encompasses1,600 employees at 35 offices and sites in southeastern Michigan.
Articles in this issue
about 31 years ago
New Probe Detects Fusion of bcr/ablabout 31 years ago
Avon's Breast Cancer Crusade to Offer 'Pink Ribbon' Pensabout 31 years ago
Take a Behind the Scenes Look at ODACabout 31 years ago
High-Dose Chemo Patients to Get Stem Cells With the MDR-1 Geneabout 31 years ago
Report on Minority Health Finds Few Black Oncologistsabout 31 years ago
Where Are We Going and What Questions Do We Need to Ask?about 31 years ago
Phase I Trial of Circadian Patterned Infusion of Continuous IL-2 Opensabout 31 years ago
Hodgkin's Disease Patients Sought for Trial of MoAbabout 31 years ago
New Health Care Insurance Reform Legislation Introduced in the SenateAdvertisement
Related to this article
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Jasmine Zain, MD, described how pre-existing CHIP mutations should inform pre-infusion risk counseling and treatment selection.
T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5